­
­
­
­

Inventi Rapid - Pharmacokinetics & Pharmacodynamics

Articles

  • Inventi:pkd/60/12
    PHARMACOLOGY OF RIVASTIGMINE: A COST SAVING TREATMENT FOR ALZHEIMER’S DISEASE DEMENTIA
    Puneet KR Gupta*, Payal R Dande, Puja Gupta

    Rivastigmine is an effective reversible acetyl cholinesterase inhibitor used for the treatment of mild to moderate dementia. It was approved by US Food and drug administration for Alzheimer’s disease dementia. In this review, the advances of Alzheimer’s disease dementia and pharmacokinetics and pharmacodynamic properties, efficacy and tolerability profile new clinical approaches, adverse events and serious adverse events, drug interaction and pharmacoeconomics of rivastigmine were concluded and summarised. In the clinical trials conducted on rivastigmine, stated that it is effective against cognitive functions, global function such as memory, language, attention and problem solving ability and behaviour in patient with mild to moderate Alzheimer’s disease dementia for upto 52 weeks. It is completely. In comparison with parent drug Rivastigmine has at least 10 fold lower activity against AChE. Occurred adverse events are mild and affect the gastrointestinal tract. In clinical trials rivastigmine have not shown clinically significant drug interactions thus drug interactions were not reported. Continuous treatments with rivastigmine for upto 52 weeks may reduce the patient caring with Alzheimer’s disease dementia. Rivastigmine has been shown to determination or uphold patient’s enactment in major 3 fields such as cognitive functions, global functions (Alzheimer’s disease dementia) and behaviour. Various clinical trials results show the efficacy and tolerability of rivastigmine with most protuberant adverse effects being gastrointestinal tract irritation.

    Download Full Text